H Lundbeck A/S

Research H Lundbeck A/S (HLUN-A) on Bullrun: valuation model: 69.2% undervalued, market cap DKK 36.56B, P/E 9.8, dividend yield 3.1%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHLUN-A
• ExchangeCO
• CountryDenmark
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyDKK
• Valuation signal69.2% undervalued
• Market capDKK 36.56B
• P/E9.8
• Dividend yield3.1%
• Financial periodFY2025
• RevenueDKK 24.63B
• Revenue growth11.9%
• Net incomeDKK 3.19B
• Free cash flowDKK 4.93B
• Gross margin82.7%

Valuation Snapshot

Bullrun's latest valuation model marks H Lundbeck A/S as 69.2% undervalued; latest market cap is DKK 36.56B; P/E is 9.8; dividend yield is 3.1%.

About H Lundbeck A/S

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.

Frequently asked questions

Is H Lundbeck A/S overvalued or undervalued?

Bullrun's valuation model currently marks H Lundbeck A/S as 69.2% undervalued.

What is H Lundbeck A/S's market cap?

H Lundbeck A/S's market capitalization is DKK 36.56B.

What is H Lundbeck A/S's P/E ratio?

H Lundbeck A/S's price-to-earnings (P/E) ratio is 9.8.

Does H Lundbeck A/S pay a dividend?

H Lundbeck A/S has a dividend yield of 3.1%.

What does H Lundbeck A/S do?

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.